MedTrace Logo

Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China

NCT00131833 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 96468

Last updated 2008-03-13

No results posted yet for this study

Summary

This study is part of International Vaccine Institute (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries. The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Hechi City in the Guangxhi province of China. The cost-effectiveness and safety of Vi vaccination will also be evaluated.

Conditions

  • Typhoid
  • Paratyphoid Fever

Interventions

BIOLOGICAL

Typhoid Vi vaccine

BIOLOGICAL

Meningococcal A (control)

Sponsors & Collaborators

  • Centers for Disease Control and Prevention

    collaborator FED

  • Hechi City Center for Disease Centrol

    collaborator UNKNOWN

  • Wellcome Trust

    collaborator OTHER

  • University of Western Ontario, Canada

    collaborator OTHER

  • International Vaccine Institute

    lead OTHER

Principal Investigators

  • Dong Baiqing, MD · Guangxi Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131833 on ClinicalTrials.gov